Cargando…

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

OBJECTIVES: To compare 1-year clinical efficacy of (1) initial triple disease-modifying antirheumatic drug therapy (iTDT) with initial methotrexate (MTX) monotherapy (iMM) and (2) different glucocorticoid (GC) bridging therapies: oral versus a single intramuscular injection in early rheumatoid arthr...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jong, P H, Hazes, J M, Han, H K, Huisman, M, van Zeben, D, van der Lubbe, P A, Gerards, A H, van Schaeybroeck, B, de Sonnaville, P B, van Krugten, M V, Luime, J J, Weel, A E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078755/ https://www.ncbi.nlm.nih.gov/pubmed/24788619 http://dx.doi.org/10.1136/annrheumdis-2013-204788

Ejemplares similares

Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial
por: Claessen, Susanne JJ, et al.
Publicado: (2009)

Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH)
por: Alves, Celina, et al.
Publicado: (2011)

Doctors’ preferences in de-escalating DMARDs in rheumatoid arthritis: a discrete choice experiment
por: Kuijper, T. Martijn, et al.
Publicado: (2017)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
por: Gremese, Elisa, et al.
Publicado: (2019)

In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis
por: Quax, Rogier AM, et al.
Publicado: (2012)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

External Validation of a Referral Rule for Axial Spondyloarthritis in Primary Care Patients with Chronic Low Back Pain
por: van Hoeven, Lonneke, et al.
Publicado: (2015)

Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine
por: Jacobs, Marleen E, et al.
Publicado: (2020)

Fatigue in early, intensively treated and tight-controlled rheumatoid arthritis patients is frequent and persistent: a prospective study
por: Walter, Margot J. M., et al.
Publicado: (2018)

Absence of ultrasound inflammation in patients presenting with arthralgia rules out the development of arthritis
por: van der Ven, Myrthe, et al.
Publicado: (2017)

Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis
por: Verstappen, M., et al.
Publicado: (2020)

Healthcare professionals’ perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis
por: Voshaar, M. J. H., et al.
Publicado: (2022)

Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?
por: Pasma, Annelieke, et al.
Publicado: (2017)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?
por: Machold, Klaus P, et al.
Publicado: (2006)

Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis
por: Quax, R. A. M., et al.
Publicado: (2015)

Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

A five-year model to assess the early cost-effectiveness of new diagnostic tests in the early diagnosis of rheumatoid arthritis
por: Buisman, Leander R., et al.
Publicado: (2016)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution
por: Verstappen, M., et al.
Publicado: (2022)

Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone
por: Edwards, Carl K., et al.
Publicado: (2012)

Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?
por: Ten Cate, D. F., et al.
Publicado: (2018)

Response to: ‘TARA Study: a new perspective on tapering drugs in RA’ by Mishra et al
por: van Mulligen, Elise, et al.
Publicado: (2020)

Increased radiographic progression of distal hand osteoarthritis occurring during biologic DMARD monotherapy for concomitant rheumatoid arthritis
por: Lechtenboehmer, C. A., et al.
Publicado: (2021)

Focus group interviews reveal reasons for differences in the perception of disease activity in rheumatoid arthritis
por: Walter, Margot J. M., et al.
Publicado: (2016)

A Blood Protein Signature Stratifies Clinical Response to csDMARD Therapy in Pediatric Uveitis
por: Wennink, Roos A. W., et al.
Publicado: (2022)

Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate
por: Batticciotto, Alberto, et al.
Publicado: (2016)

Time to minimal disease activity in relation to quality of life, productivity, and radiographic damage 1 year after diagnosis in psoriatic arthritis
por: Wervers, Kim, et al.
Publicado: (2019)

Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis
por: Wervers, Kim, et al.
Publicado: (2018)

Comparison of disease activity measures in early psoriatic arthritis in usual care
por: Wervers, Kim, et al.
Publicado: (2019)

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial
por: Wells, Alvin F, et al.
Publicado: (2018)

Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis - a systematic review of the literature
por: Ten Cate, David F, et al.
Publicado: (2013)

How to study determinants related to medication adherence in newly diagnosed polyarthritis patients for the development of a prediction instrument
por: Pasma, Annelieke, et al.
Publicado: (2014)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Prediagnosis radiological progression in rheumatoid arthritis: a novel tool to study the effects of early DMARD therapy
por: Wick, MC, et al.
Publicado: (2004)

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)
por: Mulder, Michelle L. M., et al.
Publicado: (2020)

Comment on “Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate”
por: Ravasio, Roberto
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ip3810lh61t507r5p98856d2n1